Omid Hamid, MD, on Improving Duration of Response in Refractory Melanoma With Lifileucel


The chief of research and immunotherapy at Cedars-Sinai The Angeles Clinic and Research Institute discussed updated data from the phase 2 C-144-01 study of the lifileucel TIL therapy.

"Lifileucel is a 1-time therapy. The toxicity is manageable and usually related to the preconditioning or the IL2. So, what you have is the ability to give a viable option to our patients that is a1-time option and can give durability of response.”

The investigational autologous tumor infiltrating lymphocyte (TIL) therapy lifileucel (Iovance Biotherapeutics) has demonstrated encouraging efficacy and a manageable safety profile in pooled data from 2 cohorts of patients with heavily pretreated advanced melanoma in the phase 2 C-144-01 (NCT02360579) clinical trial. Data from the study were presented at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting, November 8-12, 2022, in Boston, Massachusetts, by Amod A. Sarnaik, MD, FACS, Moffitt Cancer Center.

Investigators found that lifileucel had an objective response rate of 31.4% in the 2 cohorts, with 9 complete responses and 39 partial responses. Median duration of response(DOR) was not reached at a median follow up of 36.5 months, and 41.7% of responding patients had a DOR of 24 months or more. Median overall survival (OS) was 13.9 months, and the 12-month OS rate was 54% (95% CI: 45.6%, 61.6%)

CGTLive spoke with the study's co-author Omid Hamid, MD, chief, research and immunotherapy, Cedars-Sinai - The Angeles Clinic and Research Institute, to learn more about the C-144-01 study and the lifileucel TIL therapy. He discussed the advantages of the therapy in melanoma and how the research forwards progress for immunotherapy in solid tumors as a whole.

Click here to read more coverage of SITC 2022.

Sarnaik A. Lifileucel TIL cell monotherapy in patients with advanced melanoma after progression on immune checkpoint inhibitors (ICI) and targeted therapy: Pooled analysis of consecutive cohorts (C-144-01 study). Presented at: Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting November 8-12, 2022; Boston, Massachusetts. Abstract #789
Related Videos
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Lisa Nieland on Slowing Tumor Growth in Glioblastoma With Novel AAV Therapy
Manali Kamdar, MD, on Acclimating to Routine CAR T Practice in the Field
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Jennifer Taylor-Cousar, MD, MSCS, on Early Signals of Efficacy With Cystic Fibrosis Gene Therapy
Leigh Ramos-Platt, MD, on Looking Forward to Gene Therapy’s Growth
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Manali Kamdar, MD, on Evaluating Liso-Cel in Mantle Cell Lymphoma by Lines of Therapy, Prior BTKi
Ignacio Mata, PhD, an associate professor of neurology at the Cleveland Clinic Lerner Institute
Subhash Tripathi, PhD, on Developing Safe, Specific Engineered Treg Cell Therapy
© 2024 MJH Life Sciences

All rights reserved.